AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05522660
Drug: Immune checkpoint inhibitor
RxNorm normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy follows the current standard of care, according to the type of the primary tumour.~* For patients in cohort 1a (Melanoma, treated with ipilimumab plus nivolumab), systemic therapy consists of the combination of ipilimumab plus nivolumab.~* For patients in cohort 1b (Melanoma, treated with anti-PD-1/L1 monotherapy), systemic treatment consists of anti-PD-1/L1 monotherapy.~* For patients in cohort 2a (NSCLC, treated with targeted therapy), systemic therapy consists of targeted therapy (EGFR-, ALK- or ROS1-targeted treatment).~* For patients in cohort 2b (NSCLC, treated with anti-PD-1/L1 therapy with or without chemotherapy), systemic therapy consists of immune-checkpoint inhibition therapy (including an anti-PD-1/L1 compound) with or without chemotherapy.
Trial: NCT01093274
Drug: Polyethylene Glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 Liters solution
Trial: NCT06082531
Drug: Sodium hyaluronate injection
RxNorm normalized name: Sodium Hyaluronate Injection
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The control group was injected into the joint cavity with sodium hyaluronate injection..
Trial: NCT04981509
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04981509
Drug: Sodium Fluoride F-18
RxNorm normalized name: sodium fluoride F-18
DrugBank: Fluoride ion F-18 (DB09398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given F-18 sodium fluoride
Trial: NCT05555732
Drug: Datopotamab Deruxtecan
RxNorm normalized name: Datopotamab deruxtecan
DrugBank: Datopotamab deruxtecan (DB16410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dato-DXd will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
Trial: NCT05555732
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
Trial: NCT05555732
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
Trial: NCT05555732
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin will be administered an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
Trial: NCT05555732
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin will be administered an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
Trial: NCT05681572
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Midazolam , by a blinded nurse.
Trial: NCT05681572
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Dexmedetomidine , by a blinded nurse.
Trial: NCT06147375
Drug: Tacrolimus or Cyclosporine A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The protocol of IS withdrawal:Week 1-4 take Tacrolimus (Tac) or Cyclosporine A (CsA) once daily for weeks. Week 5-8 medication reduction to taking Tac / CsA 4 times a week . Week 9-12 reduction to taking Tac/ CsA 3 times a week. Week 13-18 reduction to taking Tac / CsA 2 times a week . Week 19-24 reduction to taking Tac/ CsA once per week. Week 25, the recipients will stop taking Tac/ CsA.
Trial: NCT06235749
Drug: sodium chloride 0.9%
RxNorm normalized name: SODIUM CHLORIDE 0.9% INJ
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of sodium chloride 0.9% IV following umbilical cord clamping
Trial: NCT05974345
Drug: Inclisiran sodium
RxNorm normalized name: inclisiran sodium
DrugBank: Inclisiran (DB14901)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Drug: Inclisiran sodium 300 mg virtually subcutaneously administered on Day 1, Month 3 (Day 90) and every 6 months thereafter until end of simulation.
Trial: NCT05974345
Drug: Ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug: Ezetimibe 10 mg virtually orally once a day until end of simulation.
Trial: NCT05974345
Drug: Evolocumab
RxNorm normalized name: Evolocumab
DrugBank: Evolocumab (DB09303)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug: Evolocumab 140 mg virtually subcutaneously administered every two weeks until end of simulation.
Trial: NCT06286254
Drug: Cycloferone
RxNorm normalized name: Cicloferon
DrugBank: Cyclo(his-pro) (DB02414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycloferone® is administered according to the instruction for medical use: 600 mg (4 tablets) once daily on day 1, 2, 4, 6 and 8.
Trial: NCT00002273
Drug: Ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00137358
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00137358
Drug: Amifostine
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05636111
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by (IV) vein
Trial: NCT05636111
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by (IV) vein
Trial: NCT05636111
Drug: Lurbinectedin
RxNorm normalized name: LURBINECTEDIN
DrugBank: Lurbinectedin (DB12674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by (IV) vein
Trial: NCT04906382
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04906382
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT04711135
Drug: Lutetium [177Lu] oxodotreotide/dotatate
DrugBank: Dotatate (DB14554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)
Trial: NCT05456685
Drug: Mirvetuximab soravtansine
RxNorm normalized name: MIRVETUXIMAB SORAVTANSINE
DrugBank: Mirvetuximab soravtansine (DB12489)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to the tumor cells carrying a tumor-associated protein called FRα. It is being developed for the treatment of participants with recurrent platinum-sensitive, high grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with FRα expression. FRα positivity will be defined by the Ventana FOLR1 Assay.
Trial: NCT05456685
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin is considered to be the treatment agent of choice in relapsed PSOC.
Trial: NCT06561854
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ICARIA schema :~40mg (20mg for ≥75yr) on day 1, 8, 15, 22 of each cycle plus~IKEMA schema :~20 mg on day 1-2, day 8-9, day 15-16 and day 22-23 of each cycle~For subjects older than 75 years or underweight (BMI \<18.5), the dexamethasone dose may be administered at a total dose of 20 mg weekly.~In both schema (ICARIA or IKEMA), dexamethasone will be administrated up to 2 cycle (Arm 1) or until disease progression (Arm2)
Trial: NCT05763823
Drug: Letermovir
RxNorm normalized name: Letermovir
DrugBank: Letermovir (DB12070)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily 240 mg or 480 mg oral tablets or IV dose
Trial: NCT05392192
Drug: ADX-629
RxNorm normalized name: ADX 102
DrugBank: Reproxalap (DB16688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized to receive both ADX-629 and placebo in one of two treatment sequences: One group of subjects will receive ADX-629 during the 1st treatment period and matching placebo during the 2nd Treatment while subjects the other sequence/group will receive the matching placebo in the 1st treatment period and ADX-629 in the 2nd treatment period.
Trial: NCT04754945
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given SC
Trial: NCT04754945
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or PO
Trial: NCT06338826
Drug: Dual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir (rDVR)
RxNorm normalized name: darunavir and ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: dual therapy without TDF or TAF but including 3TC in combination with Dolutegravir (DTG) or ritonavir-boosted Darunavir (rDVR
Trial: NCT06191250
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: one dose of durvalumab (750 mg IV)
Trial: NCT04734197
Drug: Betamethasone Sodium Phosphate 0.01%
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical corticosteroid solution
Trial: NCT04734197
Drug: Cyclosporine 0.05% Ophthalmic Emulsion
RxNorm normalized name: Cyclosporine 0.05% Ophthalmic Emulsion
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical ophthalmic emulsion
Trial: NCT04734197
Drug: Lifitegrast 5% Ophthalmic Solution
RxNorm normalized name: Lifitegrast 5% Ophthalmic Solution
DrugBank: Lifitegrast (DB11611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical ophthalmic solution
Trial: NCT06470191
Drug: B007
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: B007： Subcutaneous injection was administered on days 1 and 15
Trial: NCT06470191
Drug: Cyclosporin Capsules
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin Capsules： Orally, 3.5 mg/kg/d；
Trial: NCT05023369
Drug: Dexamethasone is a steroid drug and will be administered as an injectable solution (4mg/ml)
RxNorm normalized name: dexamethasone Drug Implant
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone will be administered as an injectable solution (4mg/ml). Every ml of this solution contains 4 mg of dexamethasone sodium phosphate, corresponding to 3 mg of dexamethasone. Thus 3 ml of solution will be injected peri-articularly (arm-A)
Trial: NCT03633955
Drug: FLT
RxNorm normalized name: FLT201
DrugBank: FLT201 (DB18419)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F18 labeled thymidine PET/CT scans will be performed before and after patient receives therapies.
Trial: NCT05371652
Drug: Rimegepant 75mg Orally Disintegrating Tablets (ODT)
RxNorm normalized name: rimegepant
DrugBank: Rimegepant (DB12457)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One rimegepant (BHV3000) 75mg orally disintegrating tablet (up to 1 tablet per day) at the time of their migraine attack
Trial: NCT05504720
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg flat dose, IV, over 30 minutes; day 1, 22, 43 (8 weeks) pre- and post-surgery, followed by post chemotherapy phase day 1 q3w for 11 cycles; max. 17 applications
Trial: NCT05504720
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: loading dose 8 mg/kg IV over 90 min: day 1 pre- and post-surgery; maintenance dose 6 mg/kg IV over 30 min: Day 22, 43 pre- and post-surgery; followed by 6 mg/kg post chemotherapy phase, day 1 q3w for 11 cycles; max. 17 applications
Trial: NCT05504720
Drug: FLOT
RxNorm normalized name: Flotetuzumab
DrugBank: Flotetuzumab (DB15223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel 50 mg/m² IV over 1 hour plus Oxaliplatin 85 mg/m² IV over 2 hours plus Folinic Acid 200 mg/m² IV over 1 hour plus 5-FU 2600 mg/m² IV over 24 hours every 2 weeks (day 1, 15, 29, 43) for 8 weeks pre- and 8 weeks post-surgery
Trial: NCT06289504
Drug: Cagrilintide
RxNorm normalized name: Cagrilintide
DrugBank: Cagrilintide (DB18887)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cagrilintide will be administered subcutaneously once weekly.
Trial: NCT06289504
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Semaglutide will be administered subcutaneously once weekly.
Trial: NCT05377333
Drug: Dulaglutide
RxNorm normalized name: DULAGLUTIDE
DrugBank: Dulaglutide (DB09045)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered SC.
Trial: NCT06289504
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin will be administered as a single dose orally 2 times during the study.
Trial: NCT06289504
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Warfarin will be administered as a single dose orally 2 times during the study.
Trial: NCT04581447
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin will start at dose of 850 mg once daily and, at one month increased to 850 mg twice daily
Trial: NCT04146298
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine will be administered prior to cell infusion.
Trial: NCT04146298
Drug: Anti-PD-1 monoclonal antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the treatment, anti-PD-1 monoclonal antibody will be administered if needed.
Trial: NCT05954104
Drug: Calcipotriol
RxNorm normalized name: Calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To evaluate the efficacy of Calcipotriol on Alopecia Areata.
Trial: NCT06442436
Drug: Nemtabrutinib
RxNorm normalized name: Nemtabrutinib
DrugBank: Nemtabrutinib (DB18866)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg nemtabrutinib (1 x 5 mg and 1 x 20 mg tablets) administered orally as a single dose.
Trial: NCT05653427
Drug: Amivantamab
RxNorm normalized name: amivantamab
DrugBank: Amivantamab (DB16695)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Amivantamab will be administered intravenously.
Trial: NCT06093841
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered according to package insert
Trial: NCT05820997
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paravertebral at the T7-10 levels bilaterally with 5 cc of 0.5% ropivacaine at each level
Trial: NCT05353140
Drug: Rivaroxaban + Clopidogre
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Previous pivotal trials have shown that in patients with atrial fibrillation and requiring antiplatelet treatment, a NOAC plus clopidogrel regimen was associated with a lower incidence of bleeding events as compared with a warfarin-based triple antithrombotic strategy. Therefore, the current expert opinions and consensus of North American Societies recommend a NOAC plus a P2Y12 inhibitor in patients with AF and PCI. In the present study, Rivaroxaban + Clopidogre are required for 45 days in LAAO group after LAAO.
Trial: NCT05353140
Drug: Aspirin + Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Aspirin + Clopidogrel are required from 46 days to 12 months after LAAO.
Trial: NCT06425926
Drug: GIM-531
RxNorm normalized name: ASIAN GINSENG 24 g in 100 mL TOPICAL LIQUID [GIM]
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIM-531 administered orally daily
Trial: NCT06425926
Drug: Anti-PD-1 monoclonal antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued treatment with anti-PD-1 therapy
Trial: NCT05426005
Drug: Cadonilimab
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadonilimab, 6 mg/kg every 2 weeks until disease progression, intolerable toxicity, or duration of treatment for 2 years
Trial: NCT06332365
Drug: Corticoid Acetonide triamcinolone 0.2%
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical application cream form twice a day for 4 weeks
Trial: NCT06332365
Drug: Hyaluronic acid 1%
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical application cream form twice a day for 4 weeks
Trial: NCT06405971
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients in the drug group took one tablet of metformin hydrochloride enteric capsule orally each day after breakfast and dinner, and the dose of each tablet was 250mg.
Trial: NCT05508867
Drug: bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion
Trial: NCT05508867
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion
Trial: NCT04383119
Drug: Trabectedin
RxNorm normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trabectedin in monotherapy
Trial: NCT04383119
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine, control arm
Trial: NCT06502990
Drug: Metreleptin
RxNorm normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency
Trial: NCT05628870
Drug: HRS-1358
RxNorm normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS-1358 or combination with Dalpiciclib Isethionate Tablets will be administered daily orally in continuous dosing over 28-day cycles.
Trial: NCT05872477
Drug: Ruxolitinib Topical
RxNorm normalized name: ruxolitinib topical
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: There will be 2 arms with intra individual comparison. Both groups will receive epidermal cell suspension (provided by Cutiss®). After 7 days the dressing will be removed. Each grafted side of the body will be randomly assigned to receive twice daily application of topical 1.5% ruxolitinib cream (Group A) or twice daily application of placebo cream (Group B). After 3 months, both sides will be treated by twice daily applications of topical ruxolitinib for 3 additional months.
Trial: NCT06235892
Drug: TACROLIMUS
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TACROLIMUS 2-3.5 ng/ml
Trial: NCT05635162
Drug: Zanubrutinib
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zanubrutinib dose is 160 mg twice daily (BD) orally (PO) on days 1-28 of each 28-day cycle.
Trial: NCT05635162
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 375 mg/m2 intravenous (IV)\* on day 1 (+/-3 days) of each 28-day cycle
Trial: NCT05660421
Drug: Itacitinib
RxNorm normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by mouth
Trial: NCT04714359
Drug: Midomafetamine HCl
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial doses per Experimental Session include 80 mg or 120 mg midomafetamine HCl, followed 1.5 to 2 hours later by a supplemental dose unless tolerability issues emerge. For an initial dose of 80 mg, a 40 mg supplemental dose will be used. For an initial dose of 120 mg, a 60 mg supplemental dose will be used. Total amounts of midomafetamine HCl to be administered per Experimental Session range from 80 mg to 180 mg.
Trial: NCT05151848
Drug: Adalimumab Injection
RxNorm normalized name: adalimumab Injection
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab Injection injected subcutaneously every other week for 78 weeks
Trial: NCT05151848
Drug: Tofacitinib 5 MG
RxNorm normalized name: tofacitinib 5 MG
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tofacitinib 5 MG BID taken orally for 78 weeks
Trial: NCT06310785
Drug: Esketamine
RxNorm normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The esketamine group used esketamine as an analgesic during induction and maintenance of anesthesia.